埃达拉:一种用于治疗ALS的新药
1Brain Science Institute and Dept of Neurology, Johns Hopkins University, Baltimore, MD 21218, USA.
肌缩侧面硬化 (ALS) 是一种致命的神经退行性疾病. 对于ALS的药物发现一直是具有挑战性的,只有两种FDA批准的药物,Riluzole和Edaravone,在改变疾病进展方面表现出有效性.
科学领域:
- 神经退行性疾病
- 药物发现和开发
- 肌缩侧硬化症 (ALS) 的研究
背景情况:
- 肌缩侧面硬化 (ALS) 是一种渐进的,致命的成年神经退行性疾病.
- 在ALS药物发现的历史中, 治疗进展之间存在重大挑战和长时间的间隔.
- 从历史上看,很少有药物干预措施在改变ALS进展过程中表现出有效性.
研究的目的:
- 综述对肌缩性侧面硬化症 (ALS) 药物发现的历史情况.
- 突出早期治疗药物的批准和新有效治疗方法的出现之间的显著时间延迟.
- 在开发可以改变ALS进展的药物方面取得的有限成功.
主要方法:
- 对美国食品和药物管理局批准的治疗肌缩侧面硬化症 (ALS) 的文献综述.
- 分析与ALS治疗有关的药物批准的历史时间表.
- 对已批准的ALS治疗方法的药理类和作用机制的检查.
主要成果:
- 美国食品和药物管理局批准了抗兴奋毒素药物Riluzole,
- 埃达拉是一种抗氧化剂, 是第二种有效改变ALS进展的药物.
- 利鲁和埃达拉之间的长时间间隔强调了ALS药物开发的困难.
结论:
- 从历史上看,治疗肌缩性侧面硬化症 (ALS) 的药物发现面临着重大障碍.
- 开发有效的ALS治疗需要持续的研究和创新.
- 这种药物数量有限, 凸显了治疗ALS的医疗需求尚未得到满足.
更多相关视频
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
08:11Methods and Tips for Intravenous Administration of Adeno-associated Virus to Rats and Evaluation of Central Nervous System Transduction
Published on: August 25, 2017
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
FDA Approved Drugs: Changes to Approved Drugs
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Alzheimer's Disease: Treatment
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
